Article
Human embryonic stem cell technologies and drug discovery
10 Mar 2009
Abstract excerpt
Development of new drugs is costly and takes huge resources into consideration. The big pharmaceutical companies are currently facing increasing developmental costs and a lower success-rate of bringing new compounds to the market. Therefore, it is now of outmost importance that the drug-hunting companies minimize late attritions due to sub-optimal pharmacokinetic properties or unexpected toxicity when entering...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
